CASI Pharmaceuticals (CASIF) Other Operating Expenses (2022 - 2025)

CASI Pharmaceuticals has reported Other Operating Expenses for 4 years, with the latest figure at $5.7 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses fell 81.67% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2025 stood at -$9.1 million (down 149.61% YoY), and the FY2025 full-year result was $20.5 million, up 4180.58% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $5.7 million, up from -$5.0 million in the prior quarter.
• The five-year high for Other Operating Expenses was $31.2 million in Q4 2024, with the low at -$29.8 million in Q4 2022.
• Historically, Other Operating Expenses has averaged -$173437.5 across 4 years, with a median of $397500.0 in 2022.
• The largest YoY upside for Other Operating Expenses was 2599.28% in 2024 against a maximum downside of 323.55% in 2024.
• CASI Pharmaceuticals' Other Operating Expenses stood at -$29.8 million in 2022, then soared by 95.81% to -$1.2 million in 2023, then surged by 2599.28% to $31.2 million in 2024, then sank by 81.67% to $5.7 million in 2025.
• The last three Other Operating Expenses figures came in at $5.7 million (Q4 2025), -$5.0 million (Q3 2025), and -$5.4 million (Q2 2025), per Business Quant data.